ID   VRK1_HUMAN              Reviewed;         396 AA.
AC   Q99986; Q3SYL2;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Serine/threonine-protein kinase VRK1;
DE            EC=2.7.11.1;
DE   AltName: Full=Vaccinia-related kinase 1;
GN   Name=VRK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal liver;
RX   PubMed=9344656; DOI=10.1006/geno.1997.4938;
RA   Nezu J., Oku A., Jones M.H., Shimane M.;
RT   "Identification of two novel human putative serine/threonine kinases,
RT   VRK1 and VRK2, with structural similarity to Vaccinia virus B1R
RT   kinase.";
RL   Genomics 45:327-331(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND MUTAGENESIS
RP   OF SER-14; THR-102; SER-125; SER-150; SER-158; SER-239; THR-305;
RP   THR-312; THR-355 AND THR-390.
RX   PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT   18 within the mdm-2 binding site of the p53 tumour suppressor
RT   protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [4]
RP   PHOSPHORYLATION AT THR-355, AND ENZYME REGULATION.
RX   PubMed=11883897; DOI=10.1006/abbi.2001.2746;
RA   Barcia R., Lopez-Borges S., Vega F.M., Lazo P.A.;
RT   "Kinetic properties of p53 phosphorylation by the human vaccinia-
RT   related kinase 1.";
RL   Arch. Biochem. Biophys. 399:1-5(2002).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=14645249; DOI=10.1074/jbc.M310813200;
RA   Nichols R.J., Traktman P.;
RT   "Characterization of three paralogous members of the Mammalian
RT   vaccinia related kinase family.";
RL   J. Biol. Chem. 279:7934-7946(2004).
RN   [6]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15105425; DOI=10.1074/jbc.M401009200;
RA   Sevilla A., Santos C.R., Vega F.M., Lazo P.A.;
RT   "Human vaccinia-related kinase 1 (VRK1) activates the ATF2
RT   transcriptional activity by novel phosphorylation on Thr-73 and Ser-62
RT   and cooperates with JNK.";
RL   J. Biol. Chem. 279:27458-27465(2004).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2)
RT   isoforms determines their different effect on p53 stability in tumour
RT   cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [8]
RP   FUNCTION.
RX   PubMed=16495336; DOI=10.1091/mbc.E05-12-1179;
RA   Nichols R.J., Wiebe M.S., Traktman P.;
RT   "The vaccinia-related kinases phosphorylate the N' terminus of BAF,
RT   regulating its interaction with DNA and its retention in the
RT   nucleus.";
RL   Mol. Biol. Cell 17:2451-2464(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RAN, AND ENZYME
RP   REGULATION.
RX   PubMed=18617507; DOI=10.1074/mcp.M700586-MCP200;
RA   Sanz-Garcia M., Lopez-Sanchez I., Lazo P.A.;
RT   "Proteomics identification of nuclear Ran GTPase as an inhibitor of
RT   human VRK1 and VRK2 (vaccinia-related kinase) activities.";
RL   Mol. Cell. Proteomics 7:2199-2214(2008).
RN   [10]
RP   INVOLVEMENT IN PCH1A.
RX   PubMed=19646678; DOI=10.1016/j.ajhg.2009.07.006;
RA   Renbaum P., Kellerman E., Jaron R., Geiger D., Segel R., Lee M.,
RA   King M.C., Levy-Lahad E.;
RT   "Spinal muscular atrophy with pontocerebellar hypoplasia is caused by
RT   a mutation in the VRK1 gene.";
RL   Am. J. Hum. Genet. 85:281-289(2009).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT SER-342, AND MUTAGENESIS OF LYS-179 AND
RP   SER-342.
RX   PubMed=19103756; DOI=10.1128/MCB.01341-08;
RA   Lopez-Sanchez I., Sanz-Garcia M., Lazo P.A.;
RT   "Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a
RT   downstream target in a pathway that induces Golgi fragmentation.";
RL   Mol. Cell. Biol. 29:1189-1201(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-342, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-342; SER-376 AND
RP   THR-378, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3-364 IN COMPLEX WITH
RP   INHIBITOR.
RG   Structural genomics consortium (SGC);
RT   "Human vaccinia-related kinase 1.";
RL   Submitted (SEP-2010) to the PDB data bank.
RN   [17]
RP   STRUCTURE BY NMR, CATALYTIC ACTIVITY, MUTAGENESIS OF SER-342 AND
RP   THR-353, AND AUTOPHOSPHORYLATION.
RX   PubMed=21543316; DOI=10.1074/jbc.M110.200162;
RA   Shin J., Chakraborty G., Bharatham N., Kang C., Tochio N., Koshiba S.,
RA   Kigawa T., Kim W., Kim K.T., Yoon H.S.;
RT   "NMR solution structure of human vaccinia-related kinase 1 (VRK1)
RT   reveals the C-terminal tail essential for its structural stability and
RT   autocatalytic activity.";
RL   J. Biol. Chem. 286:22131-22138(2011).
CC   -!- FUNCTION: Serine/threonine kinase involved in Golgi disassembly
CC       during the cell cycle: following phosphorylation by PLK3 during
CC       mitosis, required to induce Golgi fragmentation. Acts by mediating
CC       phosphorylation of downstream target protein. Phosphorylates 'Thr-
CC       18' of p53/TP53 and may thereby prevent the interaction between
CC       p53/TP53 and MDM2. Phosphorylates casein and histone H3.
CC       Phosphorylates BANF1: disrupts its ability to bind DNA, reduces
CC       its binding to LEM domain-containing proteins and causes its
CC       relocalization from the nucleus to the cytoplasm. Phosphorylates
CC       ATF2 which activates its transcriptional activity.
CC       {ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:14645249,
CC       ECO:0000269|PubMed:15105425, ECO:0000269|PubMed:16495336,
CC       ECO:0000269|PubMed:18617507, ECO:0000269|PubMed:19103756}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:21543316}.
CC   -!- ENZYME REGULATION: Active in presence of Mn(2+), Mg(2+) and
CC       Zn(2+), but is not functional with Ca(2+) or Cu(2+). Has a higher
CC       affinity for Mn(2+) than for Mg(2+). RAN inhibits its
CC       autophosphorylation and its ability to phosphorylate histone H3.
CC       {ECO:0000269|PubMed:11883897, ECO:0000269|PubMed:18617507}.
CC   -!- INTERACTION:
CC       P15336:ATF2; NbExp=5; IntAct=EBI-1769146, EBI-1170906;
CC       P38432:COIL; NbExp=9; IntAct=EBI-1769146, EBI-945751;
CC       P16104:H2AFX; NbExp=3; IntAct=EBI-1769146, EBI-494830;
CC       P05412:JUN; NbExp=5; IntAct=EBI-1769146, EBI-852823;
CC       O60934:NBN; NbExp=13; IntAct=EBI-1769146, EBI-494844;
CC       Q9H4B4:PLK3; NbExp=12; IntAct=EBI-1769146, EBI-751877;
CC       P62826:RAN; NbExp=12; IntAct=EBI-1769146, EBI-286642;
CC       O76064:RNF8; NbExp=2; IntAct=EBI-1769146, EBI-373337;
CC       P48431:SOX2; NbExp=14; IntAct=EBI-1769146, EBI-6124081;
CC       P04637:TP53; NbExp=9; IntAct=EBI-1769146, EBI-366083;
CC       Q12888:TP53BP1; NbExp=8; IntAct=EBI-1769146, EBI-396540;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton,
CC       spindle {ECO:0000250}. Note=Dispersed throughout the cell but not
CC       located on mitotic spindle or chromatids during mitosis.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in fetal
CC       liver, testis and thymus. {ECO:0000269|PubMed:9344656}.
CC   -!- PTM: Autophosphorylated at various serine and threonine residues.
CC       Autophosphorylation does not impair its ability to phosphorylate
CC       p53/TP53. Phosphorylation by PLK3 leads to induction of Golgi
CC       fragmentation during mitosis. {ECO:0000269|PubMed:11883897,
CC       ECO:0000269|PubMed:14645249, ECO:0000269|PubMed:19103756}.
CC   -!- DISEASE: Pontocerebellar hypoplasia 1A (PCH1A) [MIM:607596]: A
CC       disorder characterized by an abnormally small cerebellum and
CC       brainstem, central and peripheral motor dysfunction from birth,
CC       gliosis and spinal cord anterior horn cells degeneration
CC       resembling infantile spinal muscular atrophy. Additional features
CC       include muscle hypotonia, congenital contractures and respiratory
CC       insufficiency that is evident at birth.
CC       {ECO:0000269|PubMed:19646678}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. VRK subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/VRK1ID43556ch14q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB000449; BAA19108.1; -; mRNA.
DR   EMBL; BC103761; AAI03762.1; -; mRNA.
DR   EMBL; BC112075; AAI12076.1; -; mRNA.
DR   EMBL; BC113510; AAI13511.1; -; mRNA.
DR   CCDS; CCDS9947.1; -.
DR   RefSeq; NP_003375.1; NM_003384.2.
DR   UniGene; Hs.422662; -.
DR   PDB; 2KTY; NMR; -; A=1-360.
DR   PDB; 2KUL; NMR; -; A=1-360.
DR   PDB; 2LAV; NMR; -; A=1-361.
DR   PDB; 2RSV; NMR; -; A=1-396.
DR   PDB; 3OP5; X-ray; 2.40 A; A/B/C/D=3-364.
DR   PDB; 5UKF; X-ray; 2.40 A; A/B/C/D=3-364.
DR   PDB; 5UVF; X-ray; 2.00 A; A/B/C/D=3-364.
DR   PDBsum; 2KTY; -.
DR   PDBsum; 2KUL; -.
DR   PDBsum; 2LAV; -.
DR   PDBsum; 2RSV; -.
DR   PDBsum; 3OP5; -.
DR   PDBsum; 5UKF; -.
DR   PDBsum; 5UVF; -.
DR   ProteinModelPortal; Q99986; -.
DR   SMR; Q99986; -.
DR   BioGrid; 113282; 31.
DR   IntAct; Q99986; 18.
DR   MINT; MINT-3060185; -.
DR   STRING; 9606.ENSP00000216639; -.
DR   BindingDB; Q99986; -.
DR   ChEMBL; CHEMBL1293199; -.
DR   GuidetoPHARMACOLOGY; 2275; -.
DR   iPTMnet; Q99986; -.
DR   PhosphoSitePlus; Q99986; -.
DR   BioMuta; VRK1; -.
DR   DMDM; 45593726; -.
DR   EPD; Q99986; -.
DR   MaxQB; Q99986; -.
DR   PaxDb; Q99986; -.
DR   PeptideAtlas; Q99986; -.
DR   PRIDE; Q99986; -.
DR   DNASU; 7443; -.
DR   Ensembl; ENST00000216639; ENSP00000216639; ENSG00000100749.
DR   GeneID; 7443; -.
DR   KEGG; hsa:7443; -.
DR   UCSC; uc001yft.4; human.
DR   CTD; 7443; -.
DR   DisGeNET; 7443; -.
DR   GeneCards; VRK1; -.
DR   HGNC; HGNC:12718; VRK1.
DR   HPA; HPA000660; -.
DR   HPA; HPA017929; -.
DR   MalaCards; VRK1; -.
DR   MIM; 602168; gene.
DR   MIM; 607596; phenotype.
DR   neXtProt; NX_Q99986; -.
DR   OpenTargets; ENSG00000100749; -.
DR   Orphanet; 2254; Pontocerebellar hypoplasia type 1.
DR   PharmGKB; PA37330; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   eggNOG; ENOG410XPGP; LUCA.
DR   GeneTree; ENSGT00850000132311; -.
DR   HOGENOM; HOG000069991; -.
DR   HOVERGEN; HBG007532; -.
DR   InParanoid; Q99986; -.
DR   KO; K08816; -.
DR   OMA; AYRYCPD; -.
DR   OrthoDB; EOG091G05V5; -.
DR   PhylomeDB; Q99986; -.
DR   TreeFam; TF106473; -.
DR   Reactome; R-HSA-2993913; Clearance of Nuclear Envelope Membranes from Chromatin.
DR   Reactome; R-HSA-2995383; Initiation of Nuclear Envelope Reformation.
DR   SignaLink; Q99986; -.
DR   SIGNOR; Q99986; -.
DR   ChiTaRS; VRK1; human.
DR   EvolutionaryTrace; Q99986; -.
DR   GeneWiki; VRK1; -.
DR   GenomeRNAi; 7443; -.
DR   PRO; PR:Q99986; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000100749; -.
DR   CleanEx; HS_VRK1; -.
DR   ExpressionAtlas; Q99986; baseline and differential.
DR   Genevisible; Q99986; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005795; C:Golgi stack; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035175; F:histone kinase activity (H3-S10 specific); IDA:UniProtKB.
DR   GO; GO:0072354; F:histone kinase activity (H3-T3 specific); IDA:UniProtKB.
DR   GO; GO:0031493; F:nucleosomal histone binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IDA:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0090166; P:Golgi disassembly; IDA:UniProtKB.
DR   GO; GO:0043987; P:histone H3-S10 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0072355; P:histone H3-T3 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0007077; P:mitotic nuclear envelope disassembly; TAS:Reactome.
DR   GO; GO:0007084; P:mitotic nuclear envelope reassembly; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Kinase; Mitosis;
KW   Neurodegeneration; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    396       Serine/threonine-protein kinase VRK1.
FT                                /FTId=PRO_0000086803.
FT   DOMAIN       37    317       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      43     51       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    177    177       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      71     71       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     342    342       Phosphoserine; by PLK3.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19103756}.
FT   MOD_RES     355    355       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11883897}.
FT   MOD_RES     376    376       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     378    378       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MUTAGEN      14     14       S->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     102    102       T->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     125    125       S->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     150    150       S->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     158    158       S->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     179    179       K->A: Does not affect phosphorylation at
FT                                S-342. {ECO:0000269|PubMed:19103756}.
FT   MUTAGEN     239    239       S->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     305    305       T->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     312    312       T->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     342    342       S->A: Abolishes phosphorylation by PLK3
FT                                and induction of Golgi fragmentation
FT                                during mitosis. Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:19103756,
FT                                ECO:0000269|PubMed:21543316}.
FT   MUTAGEN     353    353       T->A: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:21543316}.
FT   MUTAGEN     355    355       T->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   MUTAGEN     390    390       T->A: Does not abolish
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:10951572}.
FT   TURN          2      4       {ECO:0000244|PDB:2LAV}.
FT   STRAND       11     13       {ECO:0000244|PDB:2LAV}.
FT   STRAND       22     24       {ECO:0000244|PDB:2KUL}.
FT   STRAND       28     30       {ECO:0000244|PDB:3OP5}.
FT   STRAND       36     42       {ECO:0000244|PDB:3OP5}.
FT   STRAND       46     49       {ECO:0000244|PDB:2KTY}.
FT   STRAND       50     56       {ECO:0000244|PDB:3OP5}.
FT   STRAND       59     61       {ECO:0000244|PDB:2KTY}.
FT   STRAND       67     74       {ECO:0000244|PDB:3OP5}.
FT   HELIX        78     90       {ECO:0000244|PDB:3OP5}.
FT   HELIX        93    102       {ECO:0000244|PDB:3OP5}.
FT   STRAND      113    121       {ECO:0000244|PDB:3OP5}.
FT   STRAND      124    132       {ECO:0000244|PDB:3OP5}.
FT   STRAND      134    137       {ECO:0000244|PDB:3OP5}.
FT   HELIX       138    144       {ECO:0000244|PDB:3OP5}.
FT   TURN        145    147       {ECO:0000244|PDB:2KTY}.
FT   HELIX       151    170       {ECO:0000244|PDB:3OP5}.
FT   HELIX       180    182       {ECO:0000244|PDB:3OP5}.
FT   STRAND      183    188       {ECO:0000244|PDB:3OP5}.
FT   STRAND      193    195       {ECO:0000244|PDB:3OP5}.
FT   HELIX       198    200       {ECO:0000244|PDB:2KTY}.
FT   STRAND      202    205       {ECO:0000244|PDB:3OP5}.
FT   HELIX       206    208       {ECO:0000244|PDB:3OP5}.
FT   TURN        225    227       {ECO:0000244|PDB:3OP5}.
FT   HELIX       230    233       {ECO:0000244|PDB:3OP5}.
FT   HELIX       240    256       {ECO:0000244|PDB:3OP5}.
FT   HELIX       262    264       {ECO:0000244|PDB:3OP5}.
FT   HELIX       268    280       {ECO:0000244|PDB:3OP5}.
FT   HELIX       282    289       {ECO:0000244|PDB:3OP5}.
FT   STRAND      291    294       {ECO:0000244|PDB:2KTY}.
FT   HELIX       297    307       {ECO:0000244|PDB:3OP5}.
FT   STRAND      311    313       {ECO:0000244|PDB:2KTY}.
FT   HELIX       317    330       {ECO:0000244|PDB:3OP5}.
FT   STRAND      355    357       {ECO:0000244|PDB:2KTY}.
SQ   SEQUENCE   396 AA;  45476 MW;  5640C624BF059949 CRC64;
     MPRVKAAQAG RQSSAKRHLA EQFAVGEIIT DMAKKEWKVG LPIGQGGFGC IYLADMNSSE
     SVGSDAPCVV KVEPSDNGPL FTELKFYQRA AKPEQIQKWI RTRKLKYLGV PKYWGSGLHD
     KNGKSYRFMI MDRFGSDLQK IYEANAKRFS RKTVLQLSLR ILDILEYIHE HEYVHGDIKA
     SNLLLNYKNP DQVYLVDYGL AYRYCPEGVH KEYKEDPKRC HDGTIEFTSI DAHNGVAPSR
     RGDLEILGYC MIQWLTGHLP WEDNLKDPKY VRDSKIRYRE NIASLMDKCF PEKNKPGEIA
     KYMETVKLLD YTEKPLYENL RDILLQGLKA IGSKDDGKLD LSVVENGGLK AKTITKKRKK
     EIEESKEPGV EDTEWSNTQT EEAIQTRSRT RKRVQK
//
